Literature reviews, generated by AI
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
6 free credits, then one-time credit packs from $5.
La farmacoterapia de la diabetes mellitus tipo 2 (DM2) busca reducir la hiperglucemia y la hemoglobina glucosilada (HbA1c), prevenir complicaciones microvasculares y cardiovasculares, preservar la función renal y limitar los efectos adversos. La selección terapéutica debe considerar la enfermedad cardiovascular aterosclerótica, la insuficiencia cardiaca, la enfermedad renal crónica, el riesgo de hipoglucemia, el peso, la función renal, la tolerabilidad, el costo y las preferencias del paciente. Aunque la metformina continúa siendo una opción inicial apropiada para muchos pacientes, los inhibidores del cotransportador de sodio-glucosa tipo 2 (SGLT2) y los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1) ocupan un lugar prioritario cuando existen objetivos cardiorrenales o de reducción ponderal. Las sulfonilureas, las tiazolidinedionas, los inhibidores de la dipeptidil-peptidasa 4 (DPP-4) y la insulina conservan indicaciones específicas, pero presentan limitaciones relacionadas con hipoglucemia, aumento de peso, retención de líquidos o eficacia moderada. El manejo debe integrar alimentación, actividad física, educación diabetológica, seguimiento periódico y decisiones compartidas.
Question: Farmacología de la diabetes mellitus tipo 2
Read the full reviewRetroperitoneal fibrosis (RPF) is an uncommon fibroinflammatory disorder characterized by inflammatory and fibrotic tissue surrounding the abdominal aorta and iliac vessels, often encasing the ureters. Ureteral obstruction may cause hydronephrosis, acute kidney injury, chronic kidney disease, or renal failure. RPF can be idiopathic or secondary to malignancy, medications, infection, surgery, radiation, atherosclerotic inflammation, or systemic immune-mediated disease. Increasing evidence identifies immunoglobulin G4–related disease (IgG4-RD) in a substantial subset of cases previously labeled idiopathic. Diagnosis relies on cross-sectional imaging, assessment of renal and inflammatory status, and biopsy when malignancy or atypical disease is suspected. Glucocorticoids remain central treatment, supplemented by urinary decompression and steroid-sparing or biologic therapies when indicated. A phase III randomized trial found that low-dose prednisone combined with methotrexate was non-inferior to standard-dose prednisone for remission induction while reducing cumulative glucocorticoid exposure. Long-term surveillance is necessary because relapse and progressive fibrosis can occur.
Question: Retroperitoneal fibrosis
Read the full reviewObstructive sleep apnea (OSA) has been associated with diabetic peripheral neuropathy, small-fiber abnormalities, autonomic dysfunction, and electrophysiologic changes involving visual pathways. However, the available evidence is predominantly observational, heterogeneous, and vulnerable to confounding by diabetes, obesity, hypertension, vascular disease, and metabolic dysfunction. A meta-analysis found higher odds of diabetic neuropathy among patients with OSA, with the clearest signal in type 1 diabetes, while other studies reported associations between OSA severity and diabetic peripheral or corneal small-fiber abnormalities. Studies of autonomic dysfunction similarly suggest greater impairment with more severe OSA, although referral bias and comorbidity substantially limit interpretation. Evidence for generalized idiopathic polyneuropathy, focal entrapment neuropathies, cranial neuropathy, and optic neuropathy remains insufficient. OSA screening may be reasonable in patients with cryptogenic or idiopathic neuropathy when clinical risk factors are present, but established causes should be evaluated first. Current evidence does not establish OSA as an independent cause of nerve injury or demonstrate that continuous positive airway pressure reverses established neuropathy.
Question: Obstructive Sleep apnea and neuropathies
Read the full reviewPTGS2, encoding cyclooxygenase-2 (COX-2), may influence pain through effects on prostaglandin production, inflammatory signaling, nociceptor activation, and neuronal sensitization. Available human evidence links PTGS2 variants with migraine susceptibility, cancer-pain severity, endometriosis-associated pain, postoperative and procedure-related pain, visceral hyperalgesia, osteoarthritis risk, headache duration, and response to COX-inhibiting analgesics. Reported variants include rs5277, rs1799964, rs5275, rs20417, rs689466, the −765G>C promoter polymorphism, and the −1195A/G promoter polymorphism. However, findings are heterogeneous, often based on small disease-specific studies, and generally do not directly measure pain thresholds, tolerance, or generalized nociceptive sensitivity. PTGS2 variation therefore remains a possible context-dependent modifier rather than an established universal biomarker of pain.
Question: PTGS2 genetic variants AND PAIN susceptibility and sensitivity
Read the full reviewPTGS2, encoding cyclooxygenase-2 (COX-2), contributes to inflammatory, neuropathic, and centrally maintained pain through prostaglandin production, particularly prostaglandin E₂ (PGE₂). COX-2-derived prostanoids sensitize peripheral nociceptors, while spinal and other central COX-2 pathways amplify nociceptive signaling and sustain hyperalgesia. Evidence from inflammatory models shows that selective COX-2 inhibition can suppress hyperalgesia even when oedema is minimally affected, supporting analgesic mechanisms beyond reduction of tissue swelling. Spinal COX-2/PGE₂ signaling also participates in diabetic neuropathy, injury-induced hyperalgesia, and centrally maintained hypersensitivity. However, the contribution of COX-2 varies with pain model, anatomical site, and treatment timing; it is especially prominent in central sensitization and early neuropathic pain, but is not required for every form of peripheral inflammatory hyperalgesia. These findings support COX-2 as an important but context-dependent analgesic target and motivate investigation of downstream PGE₂ synthases and receptors as potentially more selective alternatives to broad COX inhibition.
Question: PTGS2 AND PAIN
Read the full reviewNeuroplasticity reshapes how neural circuits represent, predict, perceive, and respond to temporal information. The supplied evidence indicates that experience-dependent plasticity can improve temporal discrimination, recalibrate subjective duration, adjust the rate of neural timekeeping, and organize the timing and sequencing of behavior. Auditory timing training is associated with neurochemical changes and improved performance in the inferior parietal cortex, implicating higher-order processes such as attention and temporal representation (PMID: 38316210). Reward-related dopamine signals may alter subjective timekeeping according to the timing of prediction errors and reward rates (PMID: 30864882). Plasticity also modifies neural integration windows, supports temporally structured activity during planning, and enables adaptation to changing information rates (PMID: 19582146; PMID: 26468192). In learning and rehabilitation, precisely timed feedback, repeated task-relevant practice, and circuit reorganization can improve the speed, consistency, and automatization of behavior (PMID: 41419090; PMID: 15831397; PMID: 42229417). However, the evidence concerns laboratory timing, neural learning, motor performance, and rehabilitation more directly than everyday scheduling or productivity. Neuroplasticity therefore provides an indirect biological basis for more adaptive temporal perception and behavioral timing rather than a demonstrated direct determinant of daily time management.
Question: how does neuroplasticity affect use of time?
Read the full reviewNo established treatment specifically targets or reverses Modic type 2 changes in patients with chronic sciatica or lumbar radiculopathy. These imaging findings may be associated with vertebral end-plate and adjacent marrow changes and can occur with degenerative disc disease, but they do not independently establish infection, nerve-root inflammation, or the source of sciatic symptoms. Management should therefore identify and treat the clinically concordant cause of radiculopathy, most often disc herniation or foraminal, lateral-recess, or central canal stenosis. Initial care is generally conservative and function-focused, with targeted injections considered for selected patients requiring short-term relief and decompression reserved for persistent disabling symptoms or neurological deterioration associated with confirmed nerve-root compression. Modic type 2 changes alone do not justify antibiotics, spinal fusion, or other invasive Modic-directed treatment.
Question: What's the best treatment for patients which type 2 Modic changes with chronic sciatica nerve inflammations
Read the full reviewResearch directly connecting guava (Psidium guajava) with medical technology is limited. The available evidence concerns medtech-adjacent applications, including glucose-management interventions, nutraceutical and botanical formulations, analytical quality-control methods, and biomedical assessment of therapeutic effects. A randomized clinical study found that a supercritical CO₂ guava fruit extract attenuated postprandial blood-glucose increases in healthy adults, while an experimental study of ethanolic guava leaf extract reported dose-dependent improvements in glucose and lipid profiles in diabetic rabbits, with higher doses also associated with protection against diabetes-related hepatic and renal injury (PMID: 31277259; PMID: 41689321). Additional work established an HPLC-DAD-ELSD method for quantifying nine guava triterpenoids and characterized polysaccharides with α-glucosidase-inhibitory and antioxidant activities (PMID: 32168948; PMID: 27083799). Guava bark and leaf extracts have also been evaluated in pain and osteoarthritis models using biomedical and histopathological technologies (PMID: 25386462; PMID: 28829233). Nevertheless, no identified study directly examined a medical device, diagnostic platform, sensor, or complete medtech system. Current evidence therefore supports guava primarily as a pharmacological, nutraceutical, analytical, or botanical component for future medtech-adjacent products.
Question: Medtech title guava
Read the full reviewLa extubación del paciente neurocrítico puede fracasar pese a una prueba de ventilación espontánea satisfactoria y a parámetros respiratorios convencionales adecuados. El resultado depende de la interacción entre la reserva respiratoria, el estado neurológico, la función bulbar, la protección de la vía aérea, la tos y el manejo de secreciones. La evidencia suministrada identifica como factores asociados con fracaso la tos débil o ausente, las secreciones moderadas o abundantes, la disfagia, la alteración de los reflejos protectores, un bajo componente motor del Glasgow, la ventilación mecánica prolongada y determinados indicadores de gravedad. Sin embargo, el Glasgow aislado, la modalidad de la prueba de ventilación espontánea y los índices respiratorios tradicionales tienen capacidad limitada cuando se emplean individualmente. La ecografía diafragmática, el flujo máximo de tos, la presión inspiratoria máxima y modelos como VISAGE pueden mejorar la estratificación, aunque requieren validación adicional. La decisión debe ser individualizada y multidimensional.
Question: Predictores de Extubación en neurocritico
Read the full reviewThree-dimensional prediction of T-cell receptor–peptide–major histocompatibility complex (TCR–pMHC) structures has progressed substantially, but accuracy remains dependent on the modeling strategy, complex type, structural feature, and evaluation metric. Flexible-backbone docking, specialized comparative-modeling pipelines, multimeric deep-learning architectures, and ensemble-generation methods have each addressed distinct limitations. TCRpMHCmodels, TCRmodel2, AlphaFold2, and AlphaFold3 have shown strong performance in different settings, while HADDOCK and specialized docking protocols can benefit from informative interface restraints or characteristic TCR–pMHC geometry. Nevertheless, CDR3 loops, peptide positioning, docking orientation, interface geometry, MHC class II complexes, and binding-affinity or specificity inference remain difficult. Global structural similarity may therefore obscure biologically important local errors. Current predictors are most appropriately used as complementary, hypothesis-generating tools, with model assessment based on multiple global, interface-focused, and functional criteria and with experimental validation retained as an essential step.
Question: performance of 3d structure prediction methods on TCR-pMHC complexes
Read the full review